2025-09-19 - Analysis Report
Okay, here's an analysis of TG Therapeutics Inc. (TGTX) based on the provided data, presented in English with a focus on key metrics and concise summaries.

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TGTX (TG Therapeutics Inc.) - A biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.
*   **TGTX Cumulative Return:** 69.02%
*   **VOO Cumulative Return:** 106.00%
*   **Absolute Deviation:** -37.8%
*   **Relative Deviation:** 14.2% (TGTX is positioned at the 14.2 percentile of its historical deviation range compared to VOO.)

**Analysis:** TGTX has underperformed the S&P 500 significantly. The relative deviation suggests that this underperformance is closer to the historical minimum than maximum difference.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha   | Beta   | Cap(B) |
|------------|--------|--------|---------|--------|--------|
| 2015-2017  | -6.0%  | 56.5%  | -35.0%  | -0.1   | 1.3    |
| 2016-2018  | -8.0%  | 58.6%  | -26.0%  | 0.0    | 0.7    |
| 2017-2019  | 74.0%  | 58.6%  | 44.0%   | 0.0    | 1.8    |
| 2018-2020  | 402.0% | 58.6%  | 382.0%  | -0.4   | 8.2    |
| 2019-2021  | 125.0% | 63.5%  | 76.0%   | -0.5   | 3.0    |
| 2020-2022  | -76.0% | 70.4%  | -78.0%  | -0.6   | 1.9    |
| 2021-2023  | -350.0%| 70.4%  | -368.0% | -0.8   | 2.7    |
| 2022-2024  | 71.0%  | 73.1%  | 45.0%   | -0.9   | 4.8    |
| 2023-2025  | 76.0%  | 73.1%  | 18.0%   | 0.4    | 5.2    |

**Analysis:**

*   **CAGR:** Highly volatile, ranging from -350% to +402%.
*   **MDD:** Consistently high, indicating significant downside risk.
*   **Alpha:** Generally positive during periods of strong growth, negative during downturns, showing the stock's performance is often independent of the market.
*   **Beta:** Relatively low, suggesting the stock is less sensitive to market movements than the S&P 500, and is even negative for most periods.
*   **Cap:** Market capitalization shows some growth over the periods.

**2. Recent Stock Price Movement**

*   **Current Price:** $32.61
*   **Last Market Data:** Price: $32.61, Previous Close: $32.04, Change: 1.78%
*   **5-Day Moving Average:** $32.11
*   **20-Day Moving Average:** $30.91
*   **60-Day Moving Average:** $32.94

**Analysis:** The stock price is above its 5-day and 20-day moving averages, suggesting a short-term upward trend. However, it is below its 60-day moving average, indicating a potential longer-term resistance level. The 1.78% change indicates a positive upward move.

**3. Technical Indicators and Expected Return**

*   **Market Risk Indicator (MRI):** 0.3324 (Low Risk)
*   **RSI:** 79.53 (Overbought)
*   **PPO:** 0.92
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **Recent Relative Deviation Change (20-day):** -0.7 (Negative - Short-term decline)
*   **Expected Return:** -281.0% (Long-term, relative to S&P 500)

**Analysis:**

*   **MRI:** Indicates low market risk.
*   **RSI:** The high RSI value suggests the stock is overbought and may be due for a correction.
*   **Hybrid Signal:** Recommends buying 80% of available cash, but with a "Caution" flag due to the low MRI.
*   **Recent Relative Deviation Change:**  A recent decrease in relative deviation suggests underperformance compared to the S&P 500.
*   **Expected Return:** The significantly negative expected return is a major concern, indicating projected underperformance relative to the S&P 500 over the long term. The 1.78% increase is a noteworthy event suggesting a recent positive shift that may impact short-term trading strategies.

**4. Recent News & Significant Events**

*   **[2025-09-17]** B. Riley Raises Price Target to $55 (Buy Rating).
*   **[2025-09-17]** Argus Research Decreases Rating to HOLD.
*   **[2025-09-12]** Insider Sold Shares Worth $672,268.
*   **[2025-09-10]** Data Presentations for BRIUMVIÂ® at ECTRIMS.
*   **[2025-09-08]** Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment.
*   **[2025-09-07]** $100 Million Buyback Program Launched.

**Analysis:** The news is mixed. A price target increase from B. Riley is positive, but the downgrade from Argus Research is a concern. Insider selling can sometimes be a negative signal. The BRIUMVI data presentations and trial enrollment are positive developments related to the company's pipeline. The buyback program could provide some support to the stock price.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean Rating:** 1.75 (~Buy)
*   **Opinions:** 6
*   **Target Price:** Avg: $40.83, High: $55.00, Low: $11.00
*   **Recent Rating Changes:** (No changes shown in provided data)

**Analysis:**  The analyst consensus is generally positive, with a "Buy" rating and an average target price significantly above the current price. However, the wide range between the high and low target prices indicates significant uncertainty.

**5. Recent Earnings Analysis**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-08-08 | 0.19 | $0.14B      |
| 2025-05-09 | 0.03 | $0.12B      |
| 2024-11-07 | 0.03 | $0.08B      |
| 2024-08-09 | 0.05 | $0.07B      |
| 2025-08-08 | 0.05 | $0.07B      |

**Analysis:** The most recent EPS figure is notably higher than previous quarters, indicating potential improvement in profitability. Revenue shows a general increasing trend.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-06-30   | $0.14B     | 86.58%        |
| 2025-03-31   | $0.12B     | 87.14%        |
| 2024-12-31   | $0.11B     | 85.77%        |
| 2024-09-30   | $0.08B     | 88.86%        |
| 2024-06-30   | $0.07B     | 88.70%        |

**Capital and Profitability:**

| Quarter      | Equity     | ROE           |
|--------------|------------|---------------|
| 2025-06-30   | $0.28B     | 10.20%        |
| 2025-03-31   | $0.24B     | 2.13%         |
| 2024-12-31   | $0.22B     | 10.49%        |
| 2024-09-30   | $0.19B     | 2.02%         |
| 2024-06-30   | $0.18B     | 3.87%         |

**Analysis:** Revenue is trending upwards, and profit margins are consistently high. Equity is increasing, and ROE shows volatility, with a recent improvement.

**7. Overall Analysis**

*   **Performance:** TGTX has significantly underperformed the S&P 500.
*   **Technicals:** The stock is currently overbought (high RSI), but the MRI indicates low market risk. Recent price action is positive.
*   **News & Catalysts:** Mixed news flow. Positive developments related to BRIUMVI, but analyst downgrades and insider selling are concerning. The Buyback program is a supportive measure.
*   **Financials:** Improving revenue, high profit margins, and increasing equity are positive signs. The most recent EPS figure is notably higher than previous quarters.
*   **Analyst Opinion:** Generally positive, but with a wide range in target prices, reflecting uncertainty.
*   **Expected Return:** The negative long-term expected return is a major red flag, suggesting potential underperformance relative to the market.

**Conclusion:**

TGTX presents a mixed picture. While recent financial performance (revenue, EPS, profit margins) shows improvement, the underperformance relative to the S&P 500, the negative long-term expected return, and some concerning news items (downgrade, insider selling) warrant caution. The high RSI suggests a potential short-term correction.

The stock may be suitable for short-term trading based on recent momentum, but a long-term investment should be carefully considered, especially given the negative expected return and high volatility. Further investigation into the reasons behind the projected underperformance is recommended.
